Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 11,8x - 13,0x | 12,4x |
| Selected Fwd EBIT Multiple | 6,3x - 6,9x | 6,6x |
| Fair Value | ₩4.382 - ₩4.836 | ₩4.609 |
| Upside | -17,3% - -8,8% | -13,0% |
| Benchmarks | Ticker | Full Ticker |
| Protalix BioTherapeutics, Inc. | PLX | NYSEAM:PLX |
| Amicus Therapeutics, Inc. | FOLD | NasdaqGM:FOLD |
| Dx & Vx Co., Ltd. | A180400 | KOSDAQ:A180400 |
| LabGenomics Co., Ltd. | A084650 | KOSDAQ:A084650 |
| HLB Therapeutics Co.,Ltd. | A115450 | KOSDAQ:A115450 |
| ISU Abxis Co., Ltd. | A086890 | KOSDAQ:A086890 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| PLX | FOLD | A180400 | A084650 | A115450 | A086890 | ||
| NYSEAM:PLX | NasdaqGM:FOLD | KOSDAQ:A180400 | KOSDAQ:A084650 | KOSDAQ:A115450 | KOSDAQ:A086890 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | 155.6% | 139.7% | -56.6% | -87.2% | 61.5% | -0.8% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -11.9% | -39.2% | -45.7% | 18.8% | -20.1% | -17.3% | |
| Prior Fiscal Year | 16.0% | -18.4% | -37.5% | -9.7% | -16.9% | 7.2% | |
| Latest Fiscal Year | 7.3% | 6.4% | -63.6% | -21.5% | -13.9% | 22.2% | |
| Latest Twelve Months | 13.3% | 5.8% | -94.0% | -40.2% | -6.6% | 24.1% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.30x | 5.11x | 4.34x | 1.48x | 4.11x | 3.49x | |
| EV / LTM EBITDA | 14.9x | 72.6x | -4.8x | -5.2x | 71.1x | 11.0x | |
| EV / LTM EBIT | 17.3x | 88.6x | -4.6x | -3.7x | -62.1x | 14.5x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -62.1x | -3.7x | 88.6x | ||||
| Historical EV / LTM EBIT | -25.0x | -15.4x | 11.8x | ||||
| Selected EV / LTM EBIT | 11.8x | 12.4x | 13.0x | ||||
| (x) LTM EBIT | 14,315 | 14,315 | 14,315 | ||||
| (=) Implied Enterprise Value | 168,694 | 177,573 | 186,452 | ||||
| (-) Non-shareholder Claims * | 2,953 | 2,953 | 2,953 | ||||
| (=) Equity Value | 171,647 | 180,526 | 189,405 | ||||
| (/) Shares Outstanding | 39.7 | 39.7 | 39.7 | ||||
| Implied Value Range | 4,327.22 | 4,551.05 | 4,774.88 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 4,327.22 | 4,551.05 | 4,774.88 | 5,300.00 | |||
| Upside / (Downside) | -18.4% | -14.1% | -9.9% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | PLX | FOLD | A180400 | A084650 | A115450 | A086890 | |
| Enterprise Value | 143 | 3,085 | 135,013 | 129,847 | 251,762 | 207,281 | |
| (+) Cash & Short Term Investments | 33 | 264 | 5,885 | 72,856 | 18,667 | 20,451 | |
| (+) Investments & Other | 0 | 0 | 13,189 | 14,849 | 65,767 | 11,822 | |
| (-) Debt | (5) | (443) | (50,399) | (49,027) | (26,811) | (29,320) | |
| (-) Other Liabilities | 0 | 0 | (2,298) | 0 | (22,601) | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 171 | 2,906 | 101,391 | 168,525 | 286,782 | 210,234 | |
| (/) Shares Outstanding | 79.7 | 308.5 | 49.2 | 74.2 | 84.0 | 39.7 | |
| Implied Stock Price | 2.14 | 9.42 | 2,060.00 | 2,270.00 | 3,415.00 | 5,300.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 2.14 | 9.42 | 2,060.00 | 2,270.00 | 3,415.00 | 5,300.00 | |
| Trading Currency | USD | USD | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |